<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041856</url>
  </required_header>
  <id_info>
    <org_study_id>farabieyehospital</org_study_id>
    <nct_id>NCT04041856</nct_id>
  </id_info>
  <brief_title>Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis</brief_title>
  <official_title>Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farabi Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Farabi Eye Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral
      keratoconjunctivitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosed EKC patients will be devided into two groups,first group will undergo
      povidone-iodine 2% eye drop four times a day and the control group will be treated only by
      artificial tear drops,they will be examined 3 months later and evaluations and data
      collections for the final comparison will be done.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 23, 2019</start_date>
  <completion_date type="Anticipated">November 22, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis</measure>
    <time_frame>3 months</time_frame>
    <description>Decreased patient's symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Povidone-iodine 2% eye drop</measure>
    <time_frame>3 months</time_frame>
    <description>Decreased viral load based on PCR results</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adenoviral Keratoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>EKC patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Povidone-iodine 2% eye drop will be prescribed four times a day All patients will learn how to improve the hygiene level in order to reduce transmission</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients will undergo observational treatments including artificial tear drop and improving hygiene level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone Ophthalmic</intervention_name>
    <description>Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis</description>
    <arm_group_label>EKC patients</arm_group_label>
    <other_name>Povidone-iodine 2%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suspected for viral conjunctivitis

        Exclusion Criteria:

          -  Allergic to iodized materials

          -  Age under 17
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohammad Soleimani, professor</last_name>
    <phone>00989121096496</phone>
    <email>Soleimani_md@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arash Mirzaei, Resident</last_name>
    <phone>00989126424299</phone>
    <email>drarashmirzaei@gmail.com</email>
  </overall_contact_backup>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Farabi Eye Hospital</investigator_affiliation>
    <investigator_full_name>mohammad soleimani</investigator_full_name>
    <investigator_title>Associate professor of ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

